Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

Blood

Volumn 122, Issue 15, 2013, Pages 2673-2682

  Chigrinova, Ekaterina ^a,b   Rinaldi, Andrea ^a   Kwee, Ivo ^a,c,d   Rossi, Davide ^e   Rancoita, Paola M V ^a,c   Strefford, Jonathan C ^f   Oscier, David ^g   Stamatopoulos, Kostas ^h,i   Papadaki, Theodora ^h   Berger, Francoise ^j   Young, Ken H ^k   Murray, Fiona ^l   Rosenquist, Richard ^l   Greiner, Timothy C ^m   Chan, Wing C ^m   Orlandi, Ester M ⁿ   Lucioni, Marco ⁿ   Marasca, Roberto ^o   Inghirami, Giorgio ^p   Ladetto, Marco ^p   Forconi, Francesco ^f,q   Cogliatti, Sergio ^r   Votavova, Hana ^s   Swerdlow, Steven H ^t   Stilgenbauer, Stephan ^u   Piris, Miguel A ^v   Matolcsy, Andras ^w   Spagnolo, Dominic ^x   Nikitin, Eugene ^y   Zamò, Alberto ^z   Gattei, Valter ^aa   Bhagat, Govind ^ab   Ott, German ^ac   Zucca, Emanuele ^b   Gaidano, Gianluca ^e   Bertoni, Francesco ^a,b   more..

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c DALLE MOLLE INSTITUTE FOR ARTIFICIAL INTELLIGENCE IDSIA   (Switzerland)

^d SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^h G PAPANICOLAOU HOSPITAL   (Greece)

ⁱ INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^j UNIVERSITÉ LYON 1   (France)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l UPPSALA UNIVERSITY   (Sweden)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF PAVIA   (Italy)

^o UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^p UNIVERSITY OF TURIN   (Italy)

^q UNIVERSITY OF SIENA   (Italy)

^r Department of Neurosurgery   (Switzerland)

^s INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^t UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^u UNIVERSITY OF ULM   (Germany)

^v HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^w SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^x PATHWEST LABORATORY MEDICINE   (Australia)

^y NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^z UNIVERSITY OF VERONA   (Italy)

^aa CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^ab New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^ac ROBERT BOSCH HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; B LYMPHOCYTE RECEPTOR; CD23 ANTIGEN; CD5 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; FLUDARABINE; GENOMIC DNA; IMMUNOGLOBULIN HEAVY CHAIN; JANUS KINASE 2; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN P53; RITUXIMAB; TRANSCRIPTION FACTOR REL; VINCRISTINE; TP53 PROTEIN, HUMAN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CARCINOGENESIS; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DNA FINGERPRINTING; ENZYME MECHANISM; FEMALE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RICHTER SYNDROME; TRISOMY 12; TUMOR GENE; CELL TRANSFORMATION; CHROMOSOME 12; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; LARGE CELL LYMPHOMA; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TRISOMY; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 12; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, P16; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; TRISOMY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891038503     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-489518     Document Type: Article

References (47)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009;27(1):1-10.
3. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391-3401.
4. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 1991;88(12):5413-5417.
5. Matolcsy A, Inghirami G, Knowles DM. Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). Blood. 1994;83(5):1363-1372.
6. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol. 1995;147(1):207-216.
7. Beà S, López-Guillermo A, Ribas M, et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am J Pathol. 2002;161(3):957-968.
8. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009;15(13): 4415-4422.
9. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
10. Scandurra M, Rossi D, Deambrogi C, et al. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematol Oncol. 2010;28(2):62-67.
11. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
12. Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-2113.
13. Deffenbacher KE, Iqbal J, Sanger W, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood. 2012;119(16): 3757-3766.
14. Mian M, Rinaldi A, Mensah AA, et al. Del (13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. Hematol Oncol. 2012;30(1):46-49.
15. Rinaldi A, Kwee I, Young KH, et al. Genome-wide high resolution DNA profiling of hairy cell leukaemia. Br J Haematol. 2013;162(4):566-569.
16. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105(36):13520-13525.
17. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
18. Mensah AA, Rinaldi A, Ponzoni M, et al. Absence of NOTCH1 gene mutations in MALT lymphomas. Br J Haematol. 2012;157(3):382-384.
19. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
20. Rinaldi A, Mian M, Kwee I, et al. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol. 2011;154(5):590-599.
21. Parker H, Rose-Zerilli MJ, Parker A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia. 2011;25(3):489-497.
22. Mosca L, Fabris S, Lionetti M, et al. Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res. 2010;16(23):5641-5653.
23. Ouillette P, Collins R, Shakhan S, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(21):6778-6790.
24. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in 112 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of 112 CLL. Haematologica. 2012;97(3):437-441.
25. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329-331.
26. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26): 2497-2506.
27. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
28. Capello D, Scandurra M, Poretti G, et al. Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol. 2010;148(2): 245-255.
29. Rinaldi A, Capello D, Scandurra M, et al. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. Br J Haematol. 2010;149(4):569-577.
30. Rinaldi A, Mensah AA, Kwee I, et al. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. Br J Haematol. 2013 Aug 21: [Epub ahead of print].
31. Jardin F, Jais JP, Molina TJ, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010;116(7):1092-1104.
32. Guney S, Jardin F, Bertrand P, et al. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes. Genes Chromosomes Cancer. 2012; 51(9):858-867.
33. Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood. 1998;91(8):2977-2984.
34. Cobo F, Martínez A, Pinyol M, et al. Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia. 2002;16(6):1028-1034.
35. Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22(3):359-372.
36. Shaffer AL III, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565-610.
37. Mian M, Scandurra M, Chigrinova E, et al. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. Ann Oncol. 2012;23(3):729-735.
38. Lia M, Carette A, Tang H, et al. Functional dissection of the chromosome 13q14 tumorsuppressor locus using transgenic mouse lines. Blood. 2012;119(13):2981-2990.
39. Rinaldi A, Mian M, Chigrinova E, et al. Genomewide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117(5): 1595-1604.
40. Scandurra M, Mian M, Greiner TC, et al. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol. 2010;151(3):221-231.
41. de Paoli L, Cerri M, Monti S, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma. 2012;54(5):1087-1090.
42. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012;120(24): 4783-4794.
43. Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18(6):590-605.
44. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010;149(4):484-497.
45. Rao E, Jiang C, Ji M, et al. The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia. 2012;26(5):1064-1072.
46. Dang CV. MYC on the path to cancer. Cell. 2012; 149(1):22-35.
47. Murawski N, Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 2010;11(11):1074-1085.